The prospects of hepatic drug delivery and gene therapy

Bibliography

• MEIJER DKF, MOLEMA GJE: Targeting of drugs to the liver. Sem. Liver Dis. (1995) 15:202–256.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of possible liver targeting ap-proaches, which focuses on various vehicles used for deliv-ery of drugs to the liver.
   Google Scholar
• HOOFNAGLE JH, LAU D: New therapies for chronic hepatitis B. J. Viral Hepatitis (1997) 4:S41–S50.
   Google Scholar
• •Three promising therapies for hepatitis B infection, antiviral chemotherapy, immunomodulation with cell-based thera-pies, vaccines or cytokines, and gene therapy such as with antisense oligonucleotides, ribozymes or viral mutants, are discussed. The most promising immediate approach to ther-apy is with the new nucleoside antivirals- lamivudine and famciclovir.
   Google Scholar
• RENSEN PCN, SCHIFFELERS RM, VERSLUIS AJ et al.: Hu-man recombinant apolipoprotein E-enriched lipo-somes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol Pharmacol. (1997) 52:445–455.
   PubMed Web of Science ®Google Scholar
• ALBRECHT C, MEIJER DF, LEBBE C et al.: Targeting ne-prozen coupled serum albumin to non-parenchymal cells reduces endotoxin-induced mortality in rats with biliary cirrhosis. Hepatology (1997) 26:1553–1559.
   PubMed Web of Science ®Google Scholar
• VANBERKEL TJC: Selective hepatic drug delivery - frombasic concept to clinical practice. Hepatology (1997) 26:1680–1681.
   PubMed Web of Science ®Google Scholar
• •A brief highlight of receptor-mediated targeting to the liver, especially, sinusoidal endothelial cells and Kupffer cells.
   Google Scholar
• HIRABAYASHI H, NISHIKAWA M, TAKAKURA Y,HASHIDA M: Development and pharmacokinetics of galactosylated poly-t-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharmaceut. Res. (1996) 13:880–884.
   PubMed Web of Science ®Google Scholar
• WU J, LIU P, ZHU JL, MADDUKURI S, ZERN MA: Increased liver up-take of liposomes and improved targeting effi-cacy by labeling with asialofetuin in rodents. Hepatol-ogy (1998) 27:772–778.
   PubMed Web of Science ®Google Scholar
• ••A report on efficiency of asialofetuin-labelled, vitamin E-containing liposomes in selectively targeting to hepatocyes.
   Google Scholar
• YOSHIOKA S, IMAEDA N, OKANO Y, MIZUKAMI Y, KATA- GIRT Y: Preferential uptake of lactosylceramide-bearing dipalmitoylphosphatidylcholine-liposomes into liver: role of membrane fluidity. Biol. Pharm. (1994) 17:640–644.
   PubMed Web of Science ®Google Scholar
• ZERN MA, KRESINA TF: Hepatic drug delivery and gene therapy. Hepatology (1997) 25:484–491.
   PubMed Web of Science ®Google Scholar
• ••A summary of an NIH-sponsored conference: Targeting ofNovel Therapeutics, to the Liver and GI Tract, (Sept. 21–22, 1995).
   Google Scholar
• WU J, ZERN MA: Modification of liposomes for liver tar- geting. J. Hepatol. (1996) 24:757–763.
   PubMed Web of Science ®Google Scholar
• ••A review of approaches to increase liver accumulation ofliposomes, and strategies to selectively target hepatocytes.
   Google Scholar
• TORCHILIN VP, TRUBETSKOY VS, WHITEMAN KR et al.:New synthetic amphophilic polymers for steric pro-tection of liposomes in vivo. J. Pharmaceut. ScL (1995) 84:1049–1053.
   PubMed Web of Science ®Google Scholar
• LITZINGER DC, BUITING AMJ, ROOIJEN AV, HUANG L: Ef-fect of liposome size on the circulation time and in-traorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta. (1994) 1190:99–107.
   PubMed Web of Science ®Google Scholar
• YU HY, UN CY: Uptake of charged liposomes by the ratliver. J. Formosan Med. Assoc. (1997) 96:409–413.
   PubMed Web of Science ®Google Scholar
• LIM HJ, MASIN D, MADDEN TD, BALLY MB: Influence ofdrug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther. (1996) 281:566–573.
   Web of Science ®Google Scholar
• HUWYLER J, YAN J, PARDRIDGE WM: Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the liver. J. Pharmacol Exp. Ther. (1997) 282:1541–1546.
   PubMed Web of Science ®Google Scholar
• WU J, KUNCIO GS, ZERN MA: Human liver growth in fi-brosis and cirrhosis. In: Liver Growth and Repair: From Basic Science to Clinical Practice. Strain AJ, Diehl AM (Eds.), Chapman & Hall, London (1998):558–576.
   Google Scholar
• KRIEGER M, HERZ J: Structures and functions of mul-tiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Ann. Rev. Biochem. (1994) 63:601–637.
   PubMed Web of Science ®Google Scholar
• SAMBRANO GR, STEINBER D: Recognition of oxida-tively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidyserine. Proc. Natl. Acad. ScL USA (1995) 92:1396–1400.
   PubMed Web of Science ®Google Scholar
• MAENO Y, FUJIOKA H, HOLLINGDALE MR et al.: Ultra-structural localization of CD36 in human hepatic sinu-soidal lining cells, hepatocytes, human hepatoma (HepG2-A16) cells, and C32 amelanotic melanoma cells. Exp. Parasitol. (1994) 79:383–390.
   PubMed Web of Science ®Google Scholar
• DAEMEN T, VELINOVA M, REGTS J et al: Different intra-hepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology (1997) 26:416–423.
   PubMed Web of Science ®Google Scholar
• TSCHAIKOWSKY K, BRAIN JD: Effects of liposome-encapsulated dichloromethylene diphosphonate on macrophage function and endotoxin-induced mortal-ity. Biochim. Biophys. Acta. (1994) 1222:323–330.
   PubMed Web of Science ®Google Scholar
• FREANSSEN EJF, JANSEN RW, VAALBURG M, MEIJER DKF:Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem. Phar-macol. (1993) 45:1215–1226.
   PubMed Web of Science ®Google Scholar
• KAMPS JAAM, MORSELT HWM, SWART PJ, MEIJER DKF,SCHERPHOF GL: Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc. Natl. Acad. ScL USA (1997) 94:11681–11685.
   PubMed Web of Science ®Google Scholar
• WU J, DANIELSSON A: Inhibition of hepatic fibrogene-sis, a review of pharmacological candidates. Scand. J. Gastroenterol. (1994) 29:385–391.
   PubMed Web of Science ®Google Scholar
• EISENSMITH RC, WOO SL: Somatic gene therapy for phenylketonuria and other hepatic deficiencies. J. In-her. Met. Dis. (1996) 19:412–423.
   PubMed Web of Science ®Google Scholar
• BARU M, AXELROD JH, NUR I: Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice. Gene (1995) 161:143–150.
   PubMed Web of Science ®Google Scholar
• MADEN J, BLUM HE: Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynu-cleotides to avian liver cells. Hepatology (1996) 24:474–481.
   PubMed Web of Science ®Google Scholar
• •A highly efficient receptor-mediated delivery system for DNA and oligodeoxynucleotides (ODNs) to avian liver cells has been established, using complexes of nonmodified hu-man adenovirus particles and a protein conjugate consisting of N-acetyl-glucosamine-modified bovine serum albumin, streptavidin and poly-L-lysine.
   Google Scholar
• OZAKI I, DUAN LX, LIU SL, POMERANZ RJ, ZERN MA: Ap-plication of ribozymes for gene therapy of liver dis-ease in alphal-antitrypsin deficiency. In: Molecular Diagnosis and Gene Therapy Blum HE, Wu CH, Wu GY (Eds.), Kluwar Academic Publishers, Dordrecht, (1996) :106–115.
   Google Scholar
• SHIMIZU K, MAITANI Y, TAKAYAMA K, NAGAI T: Formu-lation of liposomes with a soybean-derived sterygluco-side mixture and cholesterol for liver targeting. Biol. Pharm. Bull. (1997) 20: 881–886.
   PubMed Web of Science ®Google Scholar
• KAMIMOTO Y, TANABE D, TASHIRO S, HIRAOKA T, MI-YAUCHI Y: Changes in receptor-mediated endocytosis in liver sinusoidal cells after partial hepatectomy in the rat. Liver (1994) 14:141–147.
   PubMedGoogle Scholar
• ROSENG L, TOLLESHAUG H, BERG T: Uptake, intracellu-lar transport, and degradation of polyethylene glycol-modified asialofetuin in hepatocytes. J. Biol. Chem. (1992) 267:22987–22993.
   PubMed Web of Science ®Google Scholar
• BECKER S, SPIESS, KLENK HD: The asialoglycoprotein receptor is a potential liver-specific receptor for Mar-burg virus. J. Gen. Vim]. (1995) 76:393–399.
   PubMed Web of Science ®Google Scholar
• CHANG AGY, WU GY: Gene therapy: applications to the treatment of gastrointestinal and liver diseases. Gastro-enterology (1994) 106:1076–1084.
   PubMed Web of Science ®Google Scholar
• ••A leading review article delineating the strategies for genecorrection of GI and liver disorders.
   Google Scholar
• YAO T, ESPOSTI SD, HUANG L et al.: Inhibition of carbontetrachloride-induced liver injury by liposomes con-taining vitamin E. Am. J. Physiol. (1994) 267: G476–G484.
   PubMed Web of Science ®Google Scholar
• LIU SL, DEGLI ESPOSTI S, YAO T, DIEHL AM, ZERN MA: Vi-tamin E therapy of acute CC14-induced hepatic injury in mice is associated with inhibition of nuclear factor Kappa B binding. Hepatology (1995) 22:1474–1481.
   PubMed Web of Science ®Google Scholar
• RENSEN PCN, VAN DIJK MCM, HAVENAAR EC et al.: Selec-tive liver targeting of antivirals by recombinant chylo-microns - a new therapeutic approach to hepatitis B. Nature Med. (1995) 1:221–210.
   PubMed Web of Science ®Google Scholar
• ••A new development of targeting approach to the liver, usingrecombinant chylomicrons as carriers for antiviral agents to HBV infection.
   Google Scholar
• RENSEN PC, DE VRUEH RL, VAN BERKEL TJ: Targetinghepatitis B therapy to the liver. Clinical pharmacoki-netic considerations. Clin. Pharmacokinet. (1996) 31:131–155.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J: Microspheres as a drug delivery system in cancer therapy. Exp. Opin. Ther. Patents (1998) 8:153–171.
   Web of Science ®Google Scholar
• ••The present review proposes a hypothesis that the matrixmaterial and method of preparation are critical determinants in defining pharmaceutical characteristics of microspheres, which in turn dictate biologic activity.
   Google Scholar
• MAKIN AJ, HUGHES RD, WILLIAMS R: Systemic and he-patic hemodynamic changes in acute liver injury. Am. Physiol. (1997) 35:G617–G625.
   Google Scholar
• CODDE JP, LUMSDEN AJ, NAPOLI S, BURTON MA, GRAYBN: A comparative study of the anticancer efficacy of doxorubicin carrying microspheres and liposomes using a rat liver tumour model. Anticancer Res. (1993) 13:539–543.
   PubMed Web of Science ®Google Scholar
• DESOUZA P, D'SOUZA MJ: Formulation and in vitro up-take studies of polylactic co-glycolic microspheres and amino modified latex particles into rat peritoneal macrophages. Pharm. Res. (1990) 7:S162–S169.
   Google Scholar
• D'SOUZA MJ, DESOUZA P: Site specific microencapsu-lated drug targeting strategies-liver and gastrointesti-nal tract targeting. Adv. Drug Del. Rev. (1995) 17:247–254.
   Web of Science ®Google Scholar
• ENGELHARDT JF, YE X, DORANZ B, WILSON JM: Ablationof E2a in recombinant adenoviruses improves trans-gene persistence and decreases inflammatory re-sponse in mouse liver. Proc. Natl. Acad. Sci. USA (1994) 91:6196–6200.
   PubMed Web of Science ®Google Scholar
• WILSON JM: Adenovirus-mediated gene transfer toliver. Adv. Drug. Del. Rev. (1995) 17:303–307.
   Web of Science ®Google Scholar
• GAO GP, YANG Y, WILSON JM: Biology of adenovirusvectors with El and E4 deletions for liver-directed gene therapy. J. Virol. (1996) 70:8934–8943.
   PubMed Web of Science ®Google Scholar
• •The study indicates that adenovirus vectors with both El and E4 deletions may have advantages in terms of safety and efficacy over first-generation constructs for liver-directed gene therapy.
   Google Scholar
• SULLIVAN DE, DASH S, DU H, HIRAMATSU N et al: Liver- directed gene transfer in non-human primates. Hu-man Gene Ther. (1997) 8:1195–1206.
   PubMed Web of Science ®Google Scholar
• •This in vivo study concludes that adenovirus-mediated gene transfer to non-human primate livers via the portal vein or saphenous vein is efficient, but it results in transient expres-sion and is accompanied by an immune response to both vector and transgene products and acute hepatitis. Manipu-lation of the host immune response may expand potential applications of adenovirus vectors for liver-directed gene transfer.
   Google Scholar
• ASKARI FK, HITOMI Y, MAO M, WILSON JM: Completecorrection of hyperbilirubinemia in the Gunn rat model of Crigler-Najjar syndrome type I following transient in vivo adenovirus-mediated expression of human bilirubin UDP-glucuronosyltransferase. Gene Ther. (1996) 3:381–388.
   PubMed Web of Science ®Google Scholar
• KIM BH, TAKAHASHI M, TADA K et al.: Cell and genetherapy for inherited deficiency of bilirubin glucu-ronidation. j Perinatol. (1996) 16:S67–S72.
   PubMedGoogle Scholar
• ILAN Y, JONA VK, SENGUPTA K et al.: Transient immu-nosuppression with FK506 permits long-term expres-sion of therapeutic genes introduced into the liver using recombinant adenovirus in the rat. Hepatology (1997) 26:949–956.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrated that short-term FK506 treatmentaround the time of virus administration prevents the host im-mune response, permitting long-term gene therapy by re-peated administration of the recombinant virus.
   Google Scholar
• YANG Y, GREENOUGH K, WILSON JM: Transient im-mune blockade prevents formation of neutralizing an-tibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. (1996) 3:412–420.
   PubMed Web of Science ®Google Scholar
• JOOSS K, TURKA LA, WILSON JM: Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA41g. Gene Ther. (1998) 5:309–319.
   PubMed Web of Science ®Google Scholar
• ••This study indicates that inhibition of CD4+ T cell activationvia the CD28/B7 pathway at the time of virus instillation can partially interfere with both cellular and humoral immune response to adenovirus-mediated gene transfer circumvent-ing the need for chronic immune suppression.
   Google Scholar
• SNYDER RO, MIAO CH, PATIJN GA et al.: Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vec-tors. Nature Genet. (1997) 16:270–276.
   PubMed Web of Science ®Google Scholar
• ••A detailed description of preparation and purification ofAAV vectors and their therapeutical potential in gene ther-apy of hemophilia.
   Google Scholar
• FISHER KJ, GAO GP, WEITZMAN MD et al.: Transductionwith recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Vim]. (1996) 70:520–532.
   Web of Science ®Google Scholar
• LE M, OKUYAMA T, CAI SR et al.: Therapeutic levels offunctional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood (1997) 89:1254–1259.
   PubMed Web of Science ®Google Scholar
• BOWLING WM, KENNEDY SC, CAI SR et al: Portal branchocclusion safely facilitates in vivo retroviral vector transduction of rat liver. Human Gene Ther. (1996) 7:2113–2121.
   PubMed Web of Science ®Google Scholar
• GUNZBURG WH, FLEUCHAUS A, SALLER R, SALMONS B: Retroviral vector targeting for gene therapy. Cytok. Mol. Ther. (1996) 2:177–184.
   PubMedGoogle Scholar
• ••In this paper, strategies for redirecting the infection spec-trum of retroviral vectors in order to obtain cell-targeted gene delivery are discussed.
   Google Scholar
• KASAHARA N, DOZY AM, KAN YW: Tissue-specific tar-geting of retroviral vectors through ligand-receptor interactions. Science (1994) 266:1373–1375.
   PubMed Web of Science ®Google Scholar
• STRAYER DS: SV40 as an effective gene transfer vector in vivo. J. Biol. Chem. (1996) 271:24741–24746.
   PubMed Web of Science ®Google Scholar
• ••An initial report on the use of replication-deficient recombi-nant 5V40 as a vector for gene transfer in vitro and in vivo.
   Google Scholar
• STRAYER DS, MILANO J: SV40 mediates stable genetransfer in vivo. Gene Ther. (1996) 3:581–587.
   PubMed Web of Science ®Google Scholar
• STRAYER DS, KONDO R, MILANO J, DUAN LX: Use ofSV40-based vectors to transduce foreign genes to nor-mal human peripheral blood mononuclear cells. Gene Ther. (1997) 4:219–225.
   PubMed Web of Science ®Google Scholar
• ZERN MA, ZHU J, BAGASRA O, STRAYER DS: SV40-transduced genes are expressed in a high percentage of hepatocytes in vivo. Hepatology (1997) 26:196A.
   Google Scholar
• MAHATO RI, ROLLAND A, TOMLINSON E: Cationic lipid-based gene delivery systems: pharmaceutical perspec-tives. Pharmaceut. Res. (1997) 14:853–859
   PubMed Web of Science ®Google Scholar
• ••This review provides a critical discussion on cationic lipid-based gene delivery systems and their possible uses as pharmaceuticals.
   Google Scholar
• GAO X, HUANG L: Potentiation of cationic liposome- mediated gene delivery by polycations. Biochemistry (1996) 35:1027–1036.
   PubMed Web of Science ®Google Scholar
• ALINO SF, BOBADILLA M, CRESPO J, LEJARRETA M: Hu-man alpha 1-antitrypsin gene transfer to in vivo mouse hepatocytes. Human Gene Ther. (1996) 7:531–536.
   PubMed Web of Science ®Google Scholar
• TAKEHARA T, HAYASHI N, MIYAMOTO Y et al.: Expres-sion of the hepatitis C virus genome in rat liver after cationic liposome-mediated in vivo gene transfer. He-patology (1995) 21:746–751.
   PubMed Web of Science ®Google Scholar
• RUBIN J, GALANIS E, PITOT HC et al.: Phase I study of im-munotherapy of hepatic metastases of colorectal car-cinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. (1997) 4:419–425.
   PubMed Web of Science ®Google Scholar
• LEWIS JG, LIN KY, KOTHAVALE A et al.: A new serum re-sistant cytofectin for cellular delivery of antisense oli-godeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA (1996) 93:3176–3181.
   PubMed Web of Science ®Google Scholar
• SANDIG V, STRAUSS M: Liver-directed gene transfer andapplication to therapy. J. Mol. Med. (1996) 74:205–212.
   PubMed Web of Science ®Google Scholar
• LI S, HUANG L: In vivo gene transfer via intravenous ad-ministration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. (1997) 4:891–900.
   PubMed Web of Science ®Google Scholar
• ••A report of new formulation of cationic polypeptide-DNA-lipid for in vivo gene delivery, which displays better protec-tion of plasmid DNA against enzymatic digestion and gives high gene expression in the liver following intravenous administration.
   Google Scholar
• YANG JP, HUANG L: Overcoming the inhibitory effectof serum on lipofection by increasing the charge ratio of cationic liposome to DNA. Gene Ther. (1997) 4:950–960.
   PubMed Web of Science ®Google Scholar
• EASTMAN SJ, SIEGEL C, TOUSIGNANT J et al.: Biophysical characterization of cationic lipid: DNA complexes. Bio-chim. Biophys. Acta (1997) 1325:41–62.
   PubMed Web of Science ®Google Scholar
• ••One empirical study of characteristics of cationic lipid-DNAcomplexes and optimal charge ratio of the complexes for improving gene delivery efficiency.
   Google Scholar
• SCHWARTS B, BENOIST C, ABDALLAH B et al.:Lipospermine-based gene transfer into the newborn mouse brain is otimized by a low lipospermine/DNA charge ratio. Human Gene Ther. (1995) 6:1515–1524.
   PubMed Web of Science ®Google Scholar
• TEMPLETON NS, LASIC DD, FREDERIK PM et al.: Im-proved DNA: liposome complexes for increased sys-temic delivery and gene expression. Nature Biotechnol (1997) 15:647–652.
   PubMed Web of Science ®Google Scholar
• HONG KL, ZHENG WW, BAKER A, PAPAHADJOPHOULOS D: Stabilization of cationic liposome-plasmid com-plexes by polyamines and poly(ethylene glycol)-pho-spholipid conjugates for efficient in vivo gene delivery. FEBS Lett. (1997) 400:233–237.
   PubMed Web of Science ®Google Scholar
• POLLARD H, REMY JS, LOUSSOUARN G et al.: Polyeth-ylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J. Biol. Chem. (1998) 273:7507–7511.
   PubMed Web of Science ®Google Scholar
• ••This study concludes that polymers but not cationic lipidspromote gene delivery from the cytoplasm to the nucleus and that transgene expression in the nucleus is prevented by complexation with cationic lipids but not with cationic polymers.
   Google Scholar
• GILL DR, SOUTHERN KW, MOFFORD KA et al.: A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. (1997) 4:199–209.
   PubMed Web of Science ®Google Scholar
• MATTEUCCI MD, WAGNER RW: In pursuit of antisense.Nature (1996) 384:20–22.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, CONDON TP, BENNETT CF: Inhibi-tion of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits in-duction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. (1994) 269:16416–16424.
   PubMed Web of Science ®Google Scholar
• MAHATO RI, KAWABATA K, NOMURA T, TAKAKURA Y,HASHIDA M: Physicochemical and pharmacokinetic characteristics of plasmid DNA cationic liposome complexes. J. Pharmaceut. ScL (1995) 84:1267–1271.
   PubMed Web of Science ®Google Scholar
• KOIKE K, HARA T, ARAMAK Y, TAKADA S, TSUCHIYA S: Receptor-mediated gene transfer into hepatic cells us-ing asialoglycoprotein-labeled liposomes. Ann. NY Acad. Sci. (1994) 716:331–333.
   PubMed Web of Science ®Google Scholar
• BEHR JP: Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjugate Chem. (1994) 5:647–654.
   PubMed Web of Science ®Google Scholar
• KICHLER A, REMY JS, BOUSSIF O et al: Efficient gene de-livery with neutral complexes of lipospermine and thiol-reactive phospholipids. Biochem. Biophys. Res. Commun. (1995) 209:444–450.
   PubMed Web of Science ®Google Scholar
• HARA T, ARAMAKI Y, TAKADA S, KOIKE K, TSUCHIYA S:Receptor-mediated transfer of pSV2CAT DNA to a hu-man hepatoblastoma cell line Hep G2 using asialofetuin-labeled cationic liposomes. Gene (1995) 159:167–174.
   PubMed Web of Science ®Google Scholar
• LONGINO MA, BAKAN DA, WEICHERT JP, COUNSELL RE: Formulation of polyiodinated triglyceride analogues in a chylomicron remnant-like liver selective delivery vehicle. Pharmacol. Res. (1996) 13:875–879.
   Google Scholar
• HARA T, TAN Y, HUANG L: In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. Proc. Natl. Acad. Sci. USA (1997) 94:14547–14552.
   PubMed Web of Science ®Google Scholar
• •An initial report of reconstituted chylomicron remnants used as a vector for gene delivery.
   Google Scholar
• UN DY, UN SM, LIAW YF: Non-surgical treatment of he- patocellular carcinoma. J. Gastroenterol Hepatol (1997) 12:S319–S328.
   PubMed Web of Science ®Google Scholar
• HALL SJ, CHEN SH, WOO SL: The promise and reality of cancer gene therapy. Am. J. Human Genetics (1997) 61:785–789.
   PubMed Web of Science ®Google Scholar
• ••An overview of adenovirus vector-mediated transfection ofsuicide gene for genetic therapy of HCC and other tumours.
   Google Scholar
• HIRSCHOWITZ EA, OHVVADA A, PASCAL WR, RUSSI TJ, CRYSTAL RG: In vivo adenovirus-mediated gene trans-fer of the Escherichia Co/icytosine deaminase gene to human colon carcinoma-derived tumors induces che-mosensitivity to 5-fluorocytosine. Humam Gene Ther. (1995) 6:1055–1063.
   PubMed Web of Science ®Google Scholar
• KANAI F, LAN KH, SHIRATORI Y et al: In vivo gene ther-apy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cyto-sine deaminase gene. Cancer Res. (1997) 57:461–465.
   PubMed Web of Science ®Google Scholar
• SU H, CHANG JC, XU SM, KAN YW: Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidinekinase gene. Human Gene Ther. (1996) 7:463–470.
   PubMed Web of Science ®Google Scholar
• QIAN C, IDOATE M, BILBAO R et al.: Gene transfer andtherapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carci-noma. Human Gene Ther. (1997) 8:349–358.
   PubMed Web of Science ®Google Scholar
• •In vivo gene transfer efficiency was studied using intraportal injections of recombinant adenovirus carrying the lacZ re-porter gene (AdCMVlacZ), and the therapeutic efficacy of adenovirus-mediated transfer of the thymidine kinase gene of the herpes simplex virus followed by ganciclovir administration.
   Google Scholar
• VON WEIZSACKER F, WIELAND S, KOCK J et al.: Gene therapy for chronic viral hepatitis: ribozymes, an-tisense oligonucleotides, and dominant negative mu-tants. Hepatology (1997) 26:251–255.
   PubMed Web of Science ®Google Scholar
• WU GY, WU CH: Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligo-nucleotides. J. Biol. Chem. (1992) 267:12436–12439.
   PubMed Web of Science ®Google Scholar
• KORBA BE, GERIN JL: Antisense oligonucleotides are ef-fective inhibitors of hepatitis B virus replication in vi-tro. Antiviral Res. (1995) 28:225–242.
   PubMed Web of Science ®Google Scholar
• RUIZ J, WU GY: Liver-selective DNA targeting using the asialoglycoprotein receptor. Biogenic Amines (1998). (In Press.)
   Google Scholar
• ••This review focuses on general aspects related to targetingthe liver by the asialoglycoprotein receptor as well as strate-gies aimed to increase gene expression.
   Google Scholar
• NAKAZONO K, ITO Y, WU CH, WU GY: Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology (1996) 23:1297–1303.
   PubMed Web of Science ®Google Scholar
• JI W, ST CW: Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J. Viral. Hepatitis (1997) 4:167–173.
   PubMed Web of Science ®Google Scholar
• •It was demonstrated that the replication and expression of HBV can be inhibited through antisense gene transfer medi-ated by retroviral vectors and that the antisense-preC/C or antisense-preS/S may be potentially useful for clinical gene therapy against HBV.
   Google Scholar
• BRANCH AD: A hitchhiker's guide to antisense and nonsense biochemical pathways. Hepatology (1996) 24:1517–1529.
   PubMed Web of Science ®Google Scholar
• •An overview of advantages and disadvantages of antisense-mediated inhibition of gene expression.
   Google Scholar
• BECK J, NASSAL M: Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res. (1995) 23:4954–4962.
   PubMed Web of Science ®Google Scholar
• RUIZ J, WU CH, ITO Y, WU GY: Design and preparation of a multimeric self-cleaving hammerhead ribozyme. Biotechniques (1997) 22:338–345.
   PubMed Web of Science ®Google Scholar
• WELCH PJ, TRITZ R, YET S, BARBER J, YU M: Intracellular application of hairpin ribozyme genes against hepati-tis B virus. Gene Ther. (1997) 4:736–743.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO N, WU CH, WU GY: Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J. Clin. Invest. (1996) 98:2720–2728.
   PubMed Web of Science ®Google Scholar
• LIEBER A, HE CY, POLYAK SJ et al: Elimination of hepati-tis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol (1996) 70:8782–8791.
   PubMed Web of Science ®Google Scholar
• SCAGLIONI P, MELEGARI M, TAKAHASHI M, CHOWD-HURY JR, WANDS J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology (1996) 24:1010–1017.
   PubMed Web of Science ®Google Scholar
• WANDS JR, GEISSLER M, PUTLITZ JZ et al.: Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. J. Gastroenterol. Hepatol. (1997) 12:S354–S369.
   PubMed Web of Science ®Google Scholar
• ALINO SF: Long-term expression of the human al-antitrypsin gene in mice: employing anionic and cati-onic liposome vector. Biochem. PharmacoL (1997) 54:9–13.
   PubMed Web of Science ®Google Scholar
• ••A summary of the use of small anionic liposomes and cati-onic liposomes in the delivery of the human al-AT gene in mouse liver.
   Google Scholar
• CRESPO J, BLAYA C, CRESPO A, ALINO SF: Long-term ex-pression of humanal-antitrypsin gene in mice em-ploying anionic and cationic liposome vectors. Biochem. Pharmacol. (1996) 51:1309–1314.
   PubMed Web of Science ®Google Scholar
• ALINO SF, CRESPO J, BOBADILLA M et al.: Expression of human al-antitrypsin in mouse after in vivo gene transfer to hepatocytes by small liposomes. Biochem. Biophys. Res. Commun. (1994) 204:1023–1030.
   PubMed Web of Science ®Google Scholar
• KNOELL DL, WEWER MD: Clinical implications of gene therapy for alpha-sub-antitrypsin deficiency. Chest (1995) 107:535–545.
   PubMed Web of Science ®Google Scholar
• ••This comprehensive review delineates pathophysiology ofal-AT deficiency and reviews various approaches for ge-netical delivery of al-AT gene.
   Google Scholar
• KAY MA, LI Q, LIU TJ et al.: Hepatic gene therapy: persis-tent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Human Gene Therapy. (1992) 3:641–647
   PubMed Web of Science ®Google Scholar
• KAY MA, BALEY P, ROTHENBERG S et al.: Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc. Natl. Acad. Sci. USA (1992) 89:89–93.
   PubMed Web of Science ®Google Scholar
• HAFENRICHTER DG, PONDER KP, RETTINGER SD et al.: Liver-directed gene therapy: evaluation of liver spe-cific promoter elements. J. Surg. Res. (1994) 56:510–517.
   PubMed Web of Science ®Google Scholar
• OKUYAMA T, HUBER RM, BOWLING W et al.: Liver-directed gene therapy: a retroviral vector with a com-plete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of hu-man alpha 1-antitrypsin in vivo. Human Gene Ther. (1996) 7:637–645.
   PubMed Web of Science ®Google Scholar
• SCHIEDNER G, MORRAL N, PARKS RJ et al.: Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. (1998) 18:180–183.
   PubMed Web of Science ®Google Scholar
• EISENSMITH RC, WOO SL: Viral vector-mediated gene therapy for hemophilia B. Thrombosis Haemostasis (1997) 78:24–30.
   PubMed Web of Science ®Google Scholar
• KAY MA: Hepatic gene therapy for hemophilia B. In: In-hibitors to Coagulation Factors, Aledort LM et al., (Eds.), Ple-num Press, New York (1995):229–234.
   Google Scholar
• GROVE RI, WU GY: Preclinical trials using hepatic gene therapy. Adv. Drug Del. Revs. (1998) 30:199–204.
   PubMedGoogle Scholar
• ••This review outlines the more commonly used approachesand discusses the progress that has been made toward de-veloping a widely applicable, clinically relevant gene trans-fer procedure for the liver.
   Google Scholar
• OVYANG EC, WU GY: Gene therapy: recent advances and application in gastroenterology and hepatology. J. Gastroenterol. Hepatol (1998) (In Press.)
   Google Scholar
• ••An extensive overview of progress in the development ofvectors for gene therapy, as well as a description of experi-mental and clinical trials for the correction of the genetic de-ficiencies, viral hepatitis, and hepatocellular carcinoma.
   Google Scholar
• KOEBERL DD, ALEXANDER IE, HALBERT CL, RUSSELL DW, MILLER AD: Persistent expression of human clot-ting factor IX from mouse liver after intravenous injec-tion of adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA (1997) 94:1426–1431.
   PubMed Web of Science ®Google Scholar
• ••A report of the application of AAV vectors in correction ofhemophilia in a mouse model. Injection of mice with AAV vectors encoding human clotting factor IX after 7-irradiation resulted in synthesis of low levels of human clotting factor IX for the 5-month period of observation.
   Google Scholar
• HERZOG RW, HAGSTROM JN, KUNG SH et al.: Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA (1997) 94: 5804–5809.
   PubMed Web of Science ®Google Scholar
• GROSSMAN M, RADER DJ, MULLER WM et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med. (1995) 1:1148–1154.
   PubMed Web of Science ®Google Scholar
• GROSSMAN M, RAPE SE, KOZARSKY K et al.: Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genetics (1994) 6:335–341.
   PubMed Web of Science ®Google Scholar
• RAPER SE, GROSSMAN M, RADER DJ et al: Safety and fea-sibility of liver-directed ex vivo gene therapy for ho-mozygous familial hypercholesterolemia. Ann. Surg. (1996) 223:116–126.
   PubMed Web of Science ®Google Scholar
• LI J, FANG B, EISENSMITH RC et al.: In vivo gene therapy for hyperlipidemia: phenotypic correction in Watan-abe rabbits by hepatic delivery of the rabbit LDL recep-tor gene. J. Clin. Invest. (1995) 95:768–773.
   PubMed Web of Science ®Google Scholar
• WILSON JM, GROSSMANJ M, WU CH et al.: Hepatocyte-directed gene transfer in vivo leads to transient im-provement of hypercholesterolemia in LDL receptor-deficient rabbits. J. Biol. Chem. (1992) 267:963–967.
   PubMed Web of Science ®Google Scholar
• WILSON JM, GROSSMAN M, CABRERA JM, WU CH, WU GY: A novel mechanism for achieving transgene persis-tence in vivo following somatic gene transfer into he-patocytes. J. Biol. Chem. (1992) 267:11483–11489.
   PubMed Web of Science ®Google Scholar
• GERARD RD, COLLEN D: Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. Cardiovascular Res. (1997) 35:451–458.
   PubMed Web of Science ®Google Scholar
• ••This review summarises general properties of recombinantadenovirus vectors and their application in metabolic and vascular disorders, including hypercholaesterolemia.
   Google Scholar
• ROY CHOWDHURY N, HAYS RM, BOMMINENI VR et al.: Microtubular disruption prolongs the expression of human bilirubin-uridinediphosphoglucuronate glucuronosyltransferase-1 gene transferred into Gunn rat livers. J. Biol. Chem. (1996) 271:2341–2346.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, ILAN Y, ROY CHOWDHURY N et al: Long term correction of bilirubin-UDP-glucuronosyl trans-ferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J. Biol. Chem. (1996) 271:26536–26542.
   PubMed Web of Science ®Google Scholar
• KORMIS KK, WU GY: Prospects of therapy of liver dis-eases with foreign genes. Sem. Liver Dis. (1995) 15:257–267.
   PubMed Web of Science ®Google Scholar